Merck & Co., Inc. (NYSE:MRK) Expected to Post Earnings of $1.39 Per Share

Brokerages forecast that Merck & Co., Inc. (NYSE:MRK) will report earnings per share of $1.39 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Merck & Co., Inc.’s earnings, with estimates ranging from $1.37 to $1.44. Merck & Co., Inc. posted earnings of $1.30 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.9%. The business is scheduled to announce its next earnings results before the market opens on Friday, July 31st.

On average, analysts expect that Merck & Co., Inc. will report full year earnings of $5.31 per share for the current fiscal year, with EPS estimates ranging from $5.17 to $5.40. For the next fiscal year, analysts forecast that the business will post earnings of $5.76 per share, with EPS estimates ranging from $4.52 to $6.39. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.16. The firm had revenue of $12.06 billion during the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.22 earnings per share.

A number of equities research analysts recently commented on MRK shares. Mizuho restated a “buy” rating and issued a $100.00 price objective on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. Argus reduced their price target on shares of Merck & Co., Inc. from $105.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Wolfe Research downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “peer perform” rating in a research report on Friday, June 12th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Monday, June 8th. Finally, Royal Bank of Canada reduced their price target on shares of Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating for the company in a research report on Wednesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $94.15.

In other Merck & Co., Inc. news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the sale, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $387,702. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.28% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. American Trust Investment Advisors LLC grew its stake in Merck & Co., Inc. by 4.4% in the 4th quarter. American Trust Investment Advisors LLC now owns 2,801 shares of the company’s stock worth $255,000 after acquiring an additional 118 shares during the period. Acropolis Investment Management LLC grew its stake in Merck & Co., Inc. by 4.2% in the 1st quarter. Acropolis Investment Management LLC now owns 3,056 shares of the company’s stock worth $235,000 after acquiring an additional 122 shares during the period. D Orazio & Associates Inc. grew its stake in Merck & Co., Inc. by 20.3% in the 1st quarter. D Orazio & Associates Inc. now owns 722 shares of the company’s stock worth $56,000 after acquiring an additional 122 shares during the period. Successful Portfolios LLC grew its stake in Merck & Co., Inc. by 1.7% in the 1st quarter. Successful Portfolios LLC now owns 7,696 shares of the company’s stock worth $592,000 after acquiring an additional 125 shares during the period. Finally, Eagle Ridge Investment Management grew its stake in Merck & Co., Inc. by 2.4% in the 1st quarter. Eagle Ridge Investment Management now owns 5,417 shares of the company’s stock worth $417,000 after acquiring an additional 125 shares during the period. 74.33% of the stock is owned by hedge funds and other institutional investors.

NYSE:MRK traded up $1.21 during mid-day trading on Tuesday, reaching $77.33. The stock had a trading volume of 9,483,833 shares, compared to its average volume of 12,357,683. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $189.79 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 2.10 and a beta of 0.50. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.64. The business has a 50 day simple moving average of $78.27 and a 200 day simple moving average of $81.87.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.61 per share. The ex-dividend date is Friday, June 12th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.16%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 47.01%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.